

ANTIGENICS INC /DE/
Form 3
February 12, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â KLASKIN CHRISTINE M		(Month/Day/Year)	ANTIGENICS INC /DE/ [AGEN]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
162 FIFTH AVE.,Â SUITE 900			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
NEW YORK,Â NYÂ 10010			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below)	(specify below)
			VP, Finance	6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,291	D	Â
Common Stock	195	I	by husband

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	---	---	---

Edgar Filing: ANTIGENICS INC /DE/ - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option, right to buy	01/01/1999 ⁽¹⁰⁾	01/01/2008	Common Stock	9,633	\$ 6.5	D	Â
Stock Option, right to buy	02/04/2001	02/04/2010	Common Stock	1,000	\$ 13.5	D	Â
Stock Option, right to buy	01/15/2003 ⁽¹⁾	01/15/2012	Common Stock	1,000	\$ 14.52	D	Â
Stock Option, right to buy	06/07/2003 ⁽²⁾	06/07/2012	Common Stock	5,000	\$ 9	D	Â
Stock Option, right to buy	02/11/2004 ⁽³⁾	02/11/2013	Common Stock	5,000	\$ 8.99	D	Â
Stock Option, right to buy	02/18/2005 ⁽⁴⁾	02/18/2014	Common Stock	6,800	\$ 10.36	D	Â
Stock Option, right to buy	03/07/2006 ⁽⁵⁾	03/07/2015	Common Stock	7,500	\$ 6.3	D	Â
Stock Option, right to buy	03/22/2007 ⁽⁶⁾	03/22/2016	Common Stock	10,000	\$ 5.13	D	Â
Stock Option, right to buy	09/13/2007 ⁽⁷⁾	09/13/2016	Common Stock	30,000	\$ 1.74	D	Â
Stock Option, right to buy	09/15/2007 ⁽⁸⁾	09/15/2016	Common Stock	15,311	\$ 1.63	D	Â
Restricted stock	03/22/2007 ⁽⁹⁾	03/22/2008	Common Stock	1,500	\$ 0	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KLASKIN CHRISTINE M 162 FIFTH AVE. SUITE 900 NEW YORK, NY 10010	Â	Â	Â VP, Finance	Â

Signatures

Christine M. Klaskin 02/12/2008

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest in five equal annual installments beginning January 15, 2003.
- (2) Options vest in five equal annual installments beginning June 7, 2003.
- (3) Options vest in five equal annual installments beginning February 11, 2004.
- (4) Options vest in four equal annual installments beginning February 18, 2005.
- (5) Options vest in four equal annual installments beginning March 7, 2006.
- (6) Options vest in three equal annual installments beginning March 22, 2007.
- (7) Options vest in four equal annual installments beginning September 13, 2007.
- (8) Options vest 33% on September 15, 2007 and 67% on September 15, 2008.
- (9) Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests one-third on March 22, 2007 and two-thirds on March 22, 2008.
- (10) Options vest in five equal annual installments beginning January 1, 1999.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.